Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.
Yasuhiro KondohArata AzumaJun TagawaSakae HommaPublished in: American journal of respiratory and critical care medicine (2020)
Keyphrases
- idiopathic pulmonary fibrosis
- respiratory failure
- liver failure
- chronic obstructive pulmonary disease
- interstitial lung disease
- study protocol
- phase iii
- clinical trial
- phase ii
- aortic dissection
- drug induced
- extracorporeal membrane oxygenation
- recombinant human
- randomized controlled trial
- hepatitis b virus
- intensive care unit
- double blind
- placebo controlled